Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Colorectal Cancer
28-12-2001: Abgenix, Inc. (Nasdaq: ABGX) announced today the initiation of a Phase II clinical trial of ABX-EGF in patients with colorectal cancer. ABX-EGF is a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), a receptor identified in many solid tumor types. This clinical trial, the third Phase II study of ABX-EGF, is designed to assess the safety and efficacy of ABX-EGF as monotherapy in patients with metastatic colorectal cancer who have previously failed chemotherapy. ABX-EGF is being developed in collaboration with Immunex Corporation.
This multi-center, open-label Phase II study will enroll up to 100 patients. Patients will receive intravenous infusions of 2.5 mg/kg of ABX-EGF weekly over an 8-week treatment cycle, for up to 6 cycles.
"We are pleased to advance our clinical oncology program with the start of this third Phase II trial for ABX-EGF," stated R. Scott Greer, chairman and chief executive officer of Abgenix. "Our goal is to provide effective, antibody-based therapeutic options for cancer patients."
Preliminary results of an ongoing Phase I clinical trial of ABX-EGF show that it is well tolerated and shows biological activity at low doses. Thus far, three patients in the Phase I study have achieved stable disease/minor response. Other Phase II studies of ABX-EGF in kidney cancer and non-small cell lung cancer are currently ongoing.
Abgenix, Inc. (Nasdaq: ABGX) announced today the initiation of a Phase II clinical trial of ABX-EGF in patients with colorectal cancer. ABX-EGF is a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), a receptor identified in many solid tumor types. This cli ... more
Abgenix, Inc. announced today at the IBC Antibody Engineering Conference in San Diego, Calif., the launch
of new versions of XenoMouse® mice that produce fully human monoclonal antibodies that contain both lambda and kappa light chains. Other
transgenic mouse technologies in the commercia ... more
Abgenix, Inc. (Nasdaq: ABGX) today announced that it has exclusively in-licensed from Duke
University Medical Center and Johns Hopkins University a potential new target for the treatment of cancer. This target, known as EGFrvIII, is a
member of the family of epidermal growth factor recept ... more